PHAT - Phathom Pharmaceuticals, Inc.
IEX Last Trade
6.62
0.200 3.021%
Share volume: 1,191,003
Last Updated: Mon 13 Jan 2025 10:00:00 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.28%
PREVIOUS CLOSE
CHG
CHG%
$6.42
-0.32
-0.05%
Fundamental analysis
10%
Profitability
0%
Dept financing
25%
Liquidity
75%
Performance
0%
Performance
5 Days
-4.61%
1 Month
-18.67%
3 Months
-56.68%
6 Months
-47.75%
1 Year
-11.85%
2 Year
-19.95%
Key data
Stock price
$6.62
DAY RANGE
$6.36 - $6.90
52 WEEK RANGE
$6.39 - $19.71
52 WEEK CHANGE
-$11.85
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Terrie Curran
Region: US
Website: phathompharma.com
Employees: 110
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: phathompharma.com
Employees: 110
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Phathom Pharmaceuticals, Inc. focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
Recent news